2592 Stock Chart & Stats
HK$1.34
--
Market closed
HK$1.34
--
Day’s Range― - ―
52-Week RangeHK$0.90 - HK$9.58
Previous CloseN/A
VolumeN/A
Average Volume (3M)686.50K
Market Cap
HK$1.07B
Enterprise ValueHK$3.94K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding924,692,300
10 Day Avg. Volume1,081,700
30 Day Avg. Volume686,500
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cloudbreak Pharma, Inc. News
2592 FAQ
What was Cloudbreak Pharma, Inc.’s price range in the past 12 months?
Cloudbreak Pharma, Inc. lowest stock price was HK$0.90 and its highest was HK$9.58 in the past 12 months.
What is Cloudbreak Pharma, Inc.’s market cap?
Cloudbreak Pharma, Inc.’s market cap is HK$1.07B.
When is Cloudbreak Pharma, Inc.’s upcoming earnings report date?
Cloudbreak Pharma, Inc.’s upcoming earnings report date is Aug 31, 2026 which is in 4 days.
How were Cloudbreak Pharma, Inc.’s earnings last quarter?
Cloudbreak Pharma, Inc. released its earnings results on Mar 30, 2026. The company reported -HK$0.673 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Cloudbreak Pharma, Inc. overvalued?
According to Wall Street analysts Cloudbreak Pharma, Inc.’s price is currently Overvalued.
Does Cloudbreak Pharma, Inc. pay dividends?
Cloudbreak Pharma, Inc. does not currently pay dividends.
What is Cloudbreak Pharma, Inc.’s EPS estimate?
Cloudbreak Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cloudbreak Pharma, Inc. have?
Cloudbreak Pharma, Inc. has 924,692,300 shares outstanding.
What happened to Cloudbreak Pharma, Inc.’s price movement after its last earnings report?
Cloudbreak Pharma, Inc. reported an EPS of -HK$0.673 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.587%.
Which hedge fund is a major shareholder of Cloudbreak Pharma, Inc.?
Currently, no hedge funds are holding shares in HK:2592
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cloudbreak Pharma, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
66.82%
Trailing 12-Months
Company Description
Cloudbreak Pharma, Inc.
Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases. The company develops CBT-001, which is in Phase 3 clinical trial for treating pterygium; CBT-009, a topical formulation of atropine that is in Phase 1/2 study indicated for the treatment of juvenile myopia; CBT-004, a VEGF receptor inhibitor, which is in Phase 2 clinical trial for treating vascularised pinguecula; and CBT-006, a cholesterol dissolving molecule containing the active pharmaceutical ingredient of hydroxypropyl beta-cyclodextrins that is in Phase 2 clinical trial for the treatment of meibomian gland dysfunction associated dry eye disease. It also develops CBT-199 and CBT-145 for the treatment of presbyopia, a condition caused by an age-related process; CBT-007, an eye drop for enhancing success rate of glaucoma filtration surgery; and CBT-011, an antibody-drug-synergism conjugate for the treatment of diabetic macular edema. The company was founded in 2015 and is headquartered in Irvine, California.
Technical Analysis
Jacobio Pharmaceuticals Group Co., Ltd.
―
Viva Biotech Holdings
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―
Qyuns Therapeutics Co., Ltd. Class H
―
TYK Medicines, Inc. Class H
―